AGGX 8-K 11/25/08
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C., 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date Of Earliest Event
Reported): 11/25/2008
AngioGenex,
Inc.
(Exact
Name of Registrant as Specified in its Charter)
Commission
File Number: 000-26181
Nevada |
|
86-0945116 |
(State
or Other Jurisdiction of |
|
(I.R.S.
Employer |
Incorporation
or Organization) |
|
Identification
No.) |
425
Madison Ave., Suite 902, New York, New York, 10017
(Address
of Principal Executive Offices, Including Zip Code)
(212)
874-6008
(Registrants
Telephone Number, Including Area Code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant to Rule 14a-12
under the Exchange Act(17CFR240.14a-12)
o Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
o Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
Items to
be Included in this Report
Item
9.01. Financial
Statements and Exhibits.
99.1 Press
Release dated November 25, 2008 entitled AngioGenex Reviews 2008 Achievements
and Sets Goals for 2009
Signature(s)
Pursuant
to the Requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the Undersigned hereunto
duly authorized.
|
|
|
|
|
|
AngioGenex,
Inc. |
|
|
|
Dated November 25,
2008 |
By: |
/s/ Richard
Salvador |
|
Richard
Salvador |
|
President |